Search

Your search keyword '"Brighenti, Matteo"' showing total 124 results
Start Over Author "Brighenti, Matteo"
124 results on '"Brighenti, Matteo"'

1. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Published
2024
Full Text
View/download PDF

2. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

4. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research

Author

Prelaj, Arsela, primary, Ganzinelli, Monica, additional, Provenzano, Leonardo, additional, Mazzeo, Laura, additional, Viscardi, Giuseppe, additional, Metro, Giulio, additional, Galli, Giulia, additional, Agustoni, Francesco, additional, Corte, Carminia Maria Della, additional, Spagnoletti, Andrea, additional, Giani, Claudia, additional, Ferrara, Roberto, additional, Proto, Claudia, additional, Brambilla, Marta, additional, Dumitrascu, Andra Diana, additional, Inno, Alessandro, additional, Signorelli, Diego, additional, Pizzutilo, Elio Gregory, additional, Brighenti, Matteo, additional, Biello, Federica, additional, Bennati, Chiara, additional, Toschi, Luca, additional, Russano, Marco, additional, Cortellini, Alessio, additional, Catania, Chiara, additional, Bertolini, Federica, additional, Berardi, Rossana, additional, Cantini, Luca, additional, Pecci, Federica, additional, Macerelli, Marianna, additional, Emili, Rita, additional, Bareggi, Claudia, additional, Verderame, Francesco, additional, Lugini, Antonio, additional, Pisconti, Salvatore, additional, Buzzacchino, Federica, additional, Aieta, Michele, additional, Tartarone, Alfredo, additional, Spinelli, Gianpaolo, additional, Vita, Emanuele, additional, Grisanti, Salvatore, additional, Trovò, Francesco, additional, Auletta, Pietro, additional, Lorenzini, Daniele, additional, Agnelli, Luca, additional, Sangaletti, Sabina, additional, Mazzoni, Francesca, additional, Calareso, Giuseppina, additional, Ruggirello, Margherita, additional, Greco, Gabriella Francesca, additional, Vigorito, Raffaella, additional, Occhipinti, Mario, additional, Manglaviti, Sara, additional, Beninato, Teresa, additional, Leporati, Rita, additional, Ambrosini, Paolo, additional, Serino, Roberta, additional, Silvestri, Cecilia, additional, Zito, Emanuela, additional, Pedrocchi, Alessandra Chiara Laura, additional, Miskovic, Vanja, additional, de Braud, Filippo, additional, Pruneri, Giancarlo, additional, Lo Russo, Giuseppe, additional, Genova, Carlo, additional, and Vingiani, Andrea, additional

Published
2024
Full Text
View/download PDF

5. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Abstract

Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

Published
2024

6. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Author

Garassino, Marina Chiara, Whisenant, Jennifer G, Huang, Li-Ching, Trama, Annalisa, Torri, Valter, Agustoni, Francesco, Baena, Javier, Banna, Giuseppe, Berardi, Rossana, Bettini, Anna Cecilia, Bria, Emilio, Brighenti, Matteo, Cadranel, Jacques, De Toma, Alessandro, Chini, Claudio, Cortellini, Alessio, Felip, Enriqueta, Finocchiaro, Giovanna, Garrido, Pilar, Genova, Carlo, Giusti, Raffaele, Gregorc, Vanesa, Grossi, Francesco, Grosso, Federica, Intagliata, Salvatore, La Verde, Nicla, Liu, Stephen V, Mazieres, Julien, Mercadante, Edoardo, Michielin, Olivier, Minuti, Gabriele, Moro-Sibilot, Denis, Pasello, Giulia, Passaro, Antonio, Scotti, Vieri, Solli, Piergiorgio, Stroppa, Elisa, Tiseo, Marcello, Viscardi, Giuseppe, Voltolini, Luca, Wu, Yi-Long, Zai, Silvia, Pancaldi, Vera, Dingemans, Anne-Marie, Van Meerbeeck, Jan, Barlesi, Fabrice, Wakelee, Heather, Peters, Solange, and Horn, Leora

Published
2020
Full Text
View/download PDF

7. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Author

Scagliotti, Giorgio, Moro-Sibilot, Denis, Kollmeier, Jens, Favaretto, Adolfo, Cho, Eun Kyung, Grosch, Heidrun, Kimmich, Martin, Girard, Nicolas, Tsai, Chun-Ming, Hsia, Te-Chun, Brighenti, Matteo, Schumann, Christian, Wang, Xuejing Aimee, Wijayawardana, Sameera R., Gruver, Aaron M., Wallin, Johan, Mansouri, Kambiz, Wacheck, Volker, and Chang, Gee-Chen

Published
2020
Full Text
View/download PDF

8. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Borghaei, H., primary, de Marinis, F., additional, Dumoulin, D., additional, Reynolds, C., additional, Theelen, W.S.M.E., additional, Percent, I., additional, Gutierrez Calderon, V., additional, Johnson, M.L., additional, Madroszyk-Flandin, A., additional, Garon, E.B., additional, He, K., additional, Planchard, D., additional, Reck, M., additional, Popat, S., additional, Herbst, R.S., additional, Leal, T.A., additional, Shazer, R.L., additional, Yan, X., additional, Harrigan, R., additional, Peters, S., additional, Abdel-Karim, Isam, additional, Abdelsalam, Mahmoud, additional, Addeo, Alfredo, additional, Aguado, Carlos, additional, Alexander, Patrick, additional, Alt, Jürgen, additional, Azzi, Georges, additional, Balaraman, Rama, additional, Biesma, Bonne, additional, Blackhall, Fiona, additional, Bohnet, Sabine, additional, Boleti, Ekaterini, additional, Borghaei, Hossein, additional, Bradbury, Penelope, additional, Brighenti, Matteo, additional, Campbell, Nicholas, additional, Campbell, Toby, additional, Canon, Jean-Luc, additional, Cappuzzo, Federico, additional, Costa, Enric Carcereny, additional, Cavanna, Luigi, additional, Cetnar, Jeremy, additional, Chella, Antonio, additional, Chouaid, Christos, additional, Christoph, Daniel, additional, Castán, Javier Cortés, additional, Dakhil, Shaker, additional, de Castro Carpeño, Francisco Javier, additional, de Marinis, Filippo, additional, Delmonte, Angelo, additional, Demedts, Ingel, additional, Demey, Wim, additional, Dits, Joyce, additional, del Pilar Diz Taín, Maria, additional, Gómez, Manuel Dómine, additional, Dorius, Timothy, additional, Dumoulin, Daphne, additional, Duruisseaux, Michaël, additional, Eaton, Keith, additional, González, Emilio Esteban, additional, Evans, Devon, additional, Faehling, Martin, additional, Farrell, Nicholas, additional, Feinstein, Trevor, additional, Font, Enriqueta Felip, additional, Garcia Campelo, Maria Rosario, additional, Garon, Edward, additional, Garrido López, María Pilar, additional, Germonpré, Paul, additional, Gersten, Todd, additional, Cao, Maria Gonzalez, additional, Gopaluni, Srivalli, additional, Greillier, Laurent, additional, Grossi, Francesco, additional, Guisier, Florian, additional, Gurubhagavatula, Sarada, additional, Calderón, Vanesa Gutiérrez, additional, Hakimian, David, additional, Hall, Richard, additional, Hao, Desirée, additional, Harris, Ronald, additional, Hashemi, Sayed, additional, He, Kai, additional, Hendriks, Lizza, additional, Huang, Chao, additional, Ibrahim, Emad, additional, Jain, Sharad, additional, Johnson, Melissa, additional, Jones, Benjamin, additional, Jones, Monte, additional, Juan Vidal, Óscar José, additional, Juergens, Rosalyn, additional, Kaderbhai, Courèche, additional, Kastelijn, Elisabeth A (Lisanne), additional, Keresztes, Roger, additional, Kio, Ebenezer, additional, Kokowski, Konrad, additional, Konduri, Kartik, additional, Kulkarni, Swati, additional, Kuon, Jonas, additional, Kurkjian, Carla, additional, Labbé, Catherine, additional, Lerner, Rachel, additional, Lim, Farah, additional, Madroszyk-Flandin, Anne, additional, Marathe, Omkar, additional, Martincic, Danko, additional, McClay, Edward, additional, McIntyre, Kristi, additional, Mekhail, Tarek, additional, Misino, Andrea, additional, Molinier, Olivier, additional, Morabito, Alessandro, additional, Morócz, Éva, additional, Müller, Veronika, additional, Nagy, Tünde, additional, Nguyen, Anthony V., additional, Nidhiry, Emmanuel, additional, Okazaki, Ian, additional, Ortega-Granados, Ana Laura, additional, Ostoros, Gyula, additional, Oubre, David, additional, Owen, Scott, additional, Pachipala, Krishna, additional, Park, David, additional, Patel, Pareshkumar, additional, Percent, Ivor, additional, Pérol, Maurice, additional, Peters, Solange, additional, Piet, Berber, additional, Planchard, David, additional, Polychronis, Andreas, additional, Aix, Santiago Ponce, additional, Pons-Tostivint, Elvire, additional, Popat, Sanjaykumar, additional, Pulla, Mariano Provencio, additional, Quantin, Xavier, additional, Quéré, Gilles, additional, Rafique, Noman, additional, Ramaekers, Ryan, additional, Reck, Martin, additional, Reiman, Anthony, additional, Reinmuth, Niels, additional, Reynolds, Craig, additional, Rodríguez-Abreu, Delvys, additional, Romano, Gianpiero, additional, Roque, Tammy, additional, Salzberg, Matthew, additional, Sanborn, Rachel, additional, Sandiego, Sergio, additional, Schaefer, Eric, additional, Schreeder, Marshall, additional, Seetharamu, Nagashree, additional, Seneviratne, Lasika, additional, Shah, Purvi, additional, Shunyakov, Leonid, additional, Slater, Dennis, additional, Parra, Hector Soto, additional, Stigt, Johannes, additional, Stilwill, Joseph, additional, Su, Jingdong, additional, Surmont, Veerle, additional, Swink, Alicia, additional, Szalai, Zsuzsanna, additional, Talbot, Toby, additional, Garcia, Alvaro Taus, additional, Theelen, Willemijn, additional, Thompson, Jonathan, additional, Tiseo, Marcello, additional, Uprety, Dipesh, additional, Uyeki, James, additional, van der Leest, Kornelius Cor, additional, Van Ho, Anthony, additional, van Putten, John, additional, Estévez, Sergio Vázquez, additional, Veatch, Andrea, additional, Vergnenègre, Alain, additional, Ward, Patrick, additional, Weise, Amy, additional, Weiss, Matthias, additional, Whitehurst, Matthew, additional, Zai, Silvia, additional, Zalcman, Gérard, additional, and Zuniga, Richard, additional

Published
2023
Full Text
View/download PDF

12. Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres

Author

Cameli, Paolo, primary, Faverio, Paola, additional, Ferrari, Katia, additional, Bonti, Viola, additional, Marsili, Stefania, additional, Mazzei, Maria Antonietta, additional, Mazzoni, Francesca, additional, Bartolucci, Maurizio, additional, Scotti, Vieri, additional, Bertolini, Federica, additional, Barbieri, Fausto, additional, Baldessari, Cinzia, additional, Veronese, Chiara, additional, Boffi, Roberto, additional, Brighenti, Matteo, additional, Cortinovis, Diego, additional, Dominici, Massimo, additional, Pesci, Alberto, additional, Bargagli, Elena, additional, and Luppi, Fabrizio, additional

Published
2022
Full Text
View/download PDF

15. Delivery of Cancer Care at Home during the First COVID-19 Pandemic in Italy: A Case Series Study (DomOnCOVID Project)

Author

Passalacqua, Rodolfo, primary, Passalacqua, Rodolfo, additional, Ratti, Margherita, additional, Bonomi, Maria, additional, Grizzi, Giulia, additional, Negri, Federica, additional, Crea, Francesco, additional, Giganti, Mariaolga, additional, Perrucci, Bruno, additional, Brighenti, Matteo, additional, Panni, Stefano, additional, Donini, Maddalena, additional, Curti, Alessandra, additional, Spada, Daniele, additional, Marchi, Roberta, additional, Donati, Gianvito, additional, Saleri, Jessica, additional, Nazzari, Morena, additional, Pogliacomi, Giovanna, additional, Diodati, Francesca, additional, and Caminiti, Caterina, additional

Published
2021
Full Text
View/download PDF

17. Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

Author

Cortellini, Alessio, Dingemans, Anne-Marie C., Arrieta, Oscar, Baena, Javier, Brighenti, Matteo, Felip, Enriqueta, Garassino, Marina Chiara, Garrido, Pilar, Genova, Carlo, Grosso, Federica, Horn, Leora, Huang, Li-Ching, Meerbeeck, Jan, Peters, Solange, Nadal, Ernest, Rogado, Jacobo, Shyr, Yu, Tiseo, Marcello, Torri, Valter, Trama, Annalisa, Wakelee, Heather, Whisenant, Jennifer G., Viscardi, Giuseppe, Barlesi, Fabrice, Sanjay Popat, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Published
2020

19. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Author

Bersanelli, Melissa, primary, Buti, Sebastiano, additional, Giannarelli, Diana, additional, Leonetti, Alessandro, additional, Cortellini, Alessio, additional, Russo, Giuseppe Lo, additional, Signorelli, Diego, additional, Toschi, Luca, additional, Milella, Michele, additional, Pilotto, Sara, additional, Bria, Emilio, additional, Proto, Claudia, additional, Marinello, Arianna, additional, Randon, Giovanni, additional, Rossi, Sabrina, additional, Vita, Emanuele, additional, Sartori, Giulia, additional, D’Argento, Ettore, additional, Qako, Eva, additional, Giaiacopi, Elisa, additional, Ghilardi, Laura, additional, Bettini, Anna Cecilia, additional, Rapacchi, Elena, additional, Mazzoni, Francesca, additional, Lavacchi, Daniele, additional, Scotti, Vieri, additional, Ciccone, Lucia Pia, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Santini, Daniele, additional, Russano, Marco, additional, Bordi, Paola, additional, Di Maio, Massimo, additional, Audisio, Marco, additional, Filetti, Marco, additional, Giusti, Raffaele, additional, Berardi, Rossana, additional, Fiordoliva, Ilaria, additional, Cerea, Giulio, additional, Pizzutilo, Elio Gregory, additional, Bearz, Alessandra, additional, De Carlo, Elisa, additional, Cecere, Fabiana, additional, Renna, Davide, additional, Camisa, Roberta, additional, Caruso, Giuseppe, additional, Ficorella, Corrado, additional, Banna, Giuseppe Luigi, additional, Cortinovis, Diego, additional, Brighenti, Matteo, additional, Garassino, Marina Chiara, additional, and Tiseo, Marcello, additional

Published
2020
Full Text
View/download PDF

20. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases

Author

Laganà, Marta, primary, Gurizzan, Cristina, additional, Roca, Elisa, additional, Cortinovis, Diego, additional, Signorelli, Diego, additional, Pagani, Filippo, additional, Bettini, Anna, additional, Bonomi, Lucia, additional, Rinaldi, Silvia, additional, Berardi, Rossana, additional, Filetti, Marco, additional, Giusti, Raffaele, additional, Pilotto, Sara, additional, Milella, Michele, additional, Intagliata, Salvatore, additional, Baggi, Alice, additional, Cortellini, Alessio, additional, Soto Parra, Hector, additional, Brighenti, Matteo, additional, Petrelli, Fausto, additional, Bennati, Chiara, additional, Bidoli, Paolo, additional, Garassino, Marina Chiara, additional, and Berruti, Alfredo, additional

Published
2020
Full Text
View/download PDF

21. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.

Author

Andrini, Elisa, Lamberti, Giuseppe, Mazzoni, Francesca, Riccardi, Ferdinando, Bonetti, Andrea, Follador, Alessandro, Artioli, Fabrizio, Genova, Carlo, Barbieri, Fausto, Frassoldati, Antonio, Brighenti, Matteo, Colantonio, Ida, Pasello, Giulia, Ficorella, Corrado, Cinieri, Saverio, Tiseo, Marcello, Gelsomino, Francesco, Tognetto, Michele, Rihawi, Karim, and Ardizzoni, Andrea

Subjects
THERAPEUTIC use of antineoplastic agents, LUNG cancer, ETOPOSIDE, CLINICAL trials, CARBOPLATIN, LUNG tumors, MONOCLONAL antibodies
Abstract

Based on improved survival from the addition of PD-L1 inhibitors in phase III trials, the combination of immunotherapy and platinum-doublet chemotherapy has become the new standard treatment for extended-stage small-cell lung cancer (ES-SCLC). Furthermore, the antiangiogenetic agent bevacizumab showed a longer progression-free survival by targeting VEGF that has pleiotropic effects, including immunosuppressive ones. We, therefore, hypothesized that targeting angiogenesis would improve the efficacy of chemoimmunotherapy. The CeLEBrATE trial is an open-label, multicenter, phase II study designed to assess the efficacy and safety of the combination of carboplatin and etoposide plus bevacizumab and atezolizumab in treatment-naive patients with ES-SCLC. The primary end point is overall survival rate at 1 year, while secondary end points include overall response rate, progression-free survival and toxicity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

Author

Cortellini, Alessio, primary, Dingemans, Anne-Marie C., additional, Arrieta, Oscar, additional, Baena, Javier, additional, Brighenti, Matteo, additional, Felip, Enriqueta, additional, Garassino, Marina Chiara, additional, Garrido, Pilar, additional, Genova, Carlo, additional, Grosso, Federica, additional, Horn, Leora, additional, Huang, Li-Ching, additional, Van Meerbeeck, Jan, additional, Peters, Solange, additional, Nadal, Ernest, additional, Rogado, Jacobo, additional, Shyr, Yu, additional, Tiseo, Marcello, additional, Torri, Valter, additional, Trama, Annalisa, additional, Wakelee, Heather, additional, Whisenant, Jennifer G, additional, Viscardi, Giuseppe, additional, Barlesi, Fabrice, additional, and Popat, Sanjay, additional

Published
2020
Full Text
View/download PDF

23. Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Author

Petrelli, Fausto, primary, Signorelli, Diego, additional, Ghidini, Michele, additional, Ghidini, Antonio, additional, Pizzutilo, Elio Gregory, additional, Ruggieri, Lorenzo, additional, Cabiddu, Mary, additional, Borgonovo, Karen, additional, Dognini, Giuseppina, additional, Brighenti, Matteo, additional, De Toma, Alessandro, additional, Rijavec, Erika, additional, Garassino, Marina Chiara, additional, Grossi, Francesco, additional, and Tomasello, Gianluca, additional

Published
2020
Full Text
View/download PDF

26. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Author

Petrelli, Fausto, primary, Grizzi, Giulia, additional, Ghidini, Michele, additional, Ghidini, Antonio, additional, Ratti, Margherita, additional, Panni, Stefano, additional, Cabiddu, Mary, additional, Ghilardi, Mara, additional, Borgonovo, Karen, additional, Parati, Maria C., additional, Tomasello, Gianluca, additional, Barni, Sandro, additional, Berruti, Alfredo, additional, and Brighenti, Matteo, additional

Published
2019
Full Text
View/download PDF

27. Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.

Author

Grizzi, Giulia, primary, Petrelli, Fausto, additional, Ghidini, Michele, additional, Ghidini, Antonio, additional, Ratti, Margherita, additional, Panni, Stefano, additional, Cabiddu, Mary, additional, Ghilardi, Mara, additional, Borgonovo, Karen, additional, Parati, Maria Chiara, additional, Barni, Sandro, additional, Tomasello, Gianluca, additional, Passalacqua, Rodolfo, additional, Berruti, Alfredo, additional, and Brighenti, Matteo, additional

Published
2019
Full Text
View/download PDF

28. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

Author

Petrelli Fausto, Brighenti Matteo, Mandalà Mario, Verso Melina, Bonizzoni Erminio, Agnelli Giancarlo, Labianca Roberto, Barni Sandro, Bianchini Carlo, Perrone Tania, and Gasparini Giampietro

Subjects
chemotherapy, nadroparin, prophylaxis, thrombosis, LMWH, Medicine
Abstract

Abstract Background Cancer patients receiving chemotherapy are at increased risk of thrombosis. Nadroparin has been demonstrated to reduce the incidence of venous and arterial thrombotic events (TEs) by about 50% in cancer outpatients receiving chemotherapy. The aims of this retrospective analysis were to evaluate the thromboembolic risk and the benefit of thromboprophylaxis according to type of chemotherapy. Methods Cancer outpatients were randomly assigned to receive subcutaneous injections of nadroparin or placebo. The incidence of symptomatic TEs was assessed according to the type of chemotherapy. Results were reported as risk ratios with associated 95% CI and two-tailed probability values. Results 769 and 381 patients have been evaluated in the nadroparin and placebo group, respectively. In the absence of thromboprophylaxis, the highest rate of TEs was found in patients receiving gemcitabine- (8.1%) or cisplatin-based chemotherapy (7.0%). The combination of gemcitabine and cisplatin or carboplatin increased the risk to 10.2%. Thromboprophylaxis reduced TE risk by 68% in patients receiving gemcitabine; with a further decrease to 78% in those receiving a combination of gemcitabine and platinum. Conclusions This retrospective analysis confirms that patients undergoing chemotherapy including gemcitabine, platinum analogues or their combination are at higher risk of TEs. Our results also suggest that outpatients receiving chemotherapy regimens including these agents might achieve an increased benefit from thromboprophylaxis with nadroparin. Clinical Trial registration number: NCT 00951574

Published
2011
Full Text
View/download PDF

30. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

Author

Petrelli, Fausto, primary, Lazzari, Chiara, additional, Ardito, Raffaele, additional, Borgonovo, Karen, additional, Bulotta, Alessandra, additional, Conti, Barbara, additional, Cabiddu, Mary, additional, Capitanio, Jody Filippo, additional, Brighenti, Matteo, additional, Ghilardi, Mara, additional, Gianni, Luca, additional, Barni, Sandro, additional, and Gregorc, Vanesa, additional

Published
2018
Full Text
View/download PDF

33. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Author

Tiseo, Marcello, primary, Boni, Luca, additional, Ambrosio, Francesca, additional, Camerini, Andrea, additional, Baldini, Editta, additional, Cinieri, Saverio, additional, Brighenti, Matteo, additional, Zanelli, Francesca, additional, Defraia, Efisio, additional, Chiari, Rita, additional, Dazzi, Claudio, additional, Tibaldi, Carmelo, additional, Turolla, Gianni Michele, additional, D’Alessandro, Vito, additional, Zilembo, Nicoletta, additional, Trolese, Anna Rita, additional, Grossi, Francesco, additional, Riccardi, Ferdinando, additional, and Ardizzoni, Andrea, additional

Published
2017
Full Text
View/download PDF

34. Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial

Author

GRIDELLI, CESARE, primary, CHELLA, ANTONIO, additional, VALMADRE, GIUSEPPE, additional, ALLEGRINI, GIACOMO, additional, BRIGHENTI, MATTEO, additional, BIDOLI, PAOLO, additional, ROSSI, ANTONIO, additional, MAIONE, PAOLO, additional, MIGLIORINO, MARIA RITA, additional, RICCIARDI, SERENA, additional, and DE MARINIS, FILIPPO, additional

Published
2016
Full Text
View/download PDF

35. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFRMutation–Positive NSCLC Patients

Author

Scagliotti, Giorgio, Moro-Sibilot, Denis, Kollmeier, Jens, Favaretto, Adolfo, Cho, Eun Kyung, Grosch, Heidrun, Kimmich, Martin, Girard, Nicolas, Tsai, Chun-Ming, Hsia, Te-Chun, Brighenti, Matteo, Schumann, Christian, Wang, Xuejing Aimee, Wijayawardana, Sameera R., Gruver, Aaron M., Wallin, Johan, Mansouri, Kambiz, Wacheck, Volker, and Chang, Gee-Chen

Abstract

The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.

Published
2020
Full Text
View/download PDF

36. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Author

Tibaldi, Carmelo, Camerini, Andrea, Tiseo, Marcello, Mazzoni, Francesca, Barbieri, Fausto, Vittimberga, Isabella, Brighenti, Matteo, Boni, Luca, Baldini, Editta, Gilli, Annalisa, Honeywell, Richard, Chartoire, Myriam, Peters, Godefridus J., Giovannetti, Elisa, on behalf of The Italian Oncological Group of Clinical Research (GOIRC), and Italian Oncological Group of Clinical Research (GOIRC)

Abstract

Background: Cytidine deaminase (CDA) plays a crucial role in the degradation of gemcitabine. In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and efficacy of platinum/gemcitabine combinations. The aim of this prospective study was to validate the prognostic role of CDA activity in the first-line treatment of advanced non-small-cell lung cancer.Methods: A total of 124 untreated patients received standard doses of platinum/gemcitabine. CDA activity was baseline measured in plasma samples by spectrophotometric assay.Results: Using the median CDA level as cut-off, in the patients with high versus low CDA activity the response rate was 25.0% (95% CI, 14.7-37.8) and 54.1% (95% CI, 40.8-66.9), P = 0.0013; the 6-month progression rate was 34.5% (95% CI, 22.6-46.6) and 54.1% (95% CI, 40.9-65.6), HR = 2.01 (95% CI, 1.32-3.06), P < 0.001; the 1-year survival rate was 23.3% (95% CI, 13.6-34.6) and 57.3% (95% CI, 43.9-68.6), HR = 2.20 (95% CI, 1.46-3.34), P = 0.0002, respectively. CDA activity resulted to be an independent prognostic factor for progression and survival at multivariate analysis.Conclusions: This study validated prospectively the prognostic role of the CDA activity and should prompt larger and adequately designed randomised prospective studies to establish the predictive impact of this test in improving the outcome of selected patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

37. Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer

Author

Liguigli, Wanda, primary, Tomasello, Gianluca, additional, Toppo, Laura, additional, Poli, Rossana, additional, Lazzarelli, Silvia, additional, Negri, Federica, additional, Perrucci, Bruno, additional, Curti, Alessandra, additional, Brighenti, Matteo, additional, Donati, Gianvito, additional, Nazzari, Morena, additional, Martinotti, Mario, additional, Vismarra, Marco, additional, Rovatti, Massimo, additional, and Passalacqua, Rodolfo, additional

Published
2016
Full Text
View/download PDF

38. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.

Author

Tiseo, Marcello, primary, Boni, Luca, additional, Ambrosio, Francesca, additional, Camerini, Andrea, additional, Baldini, Editta, additional, Cinieri, Saverio, additional, Zanelli, Francesca, additional, Defraia, Efisio, additional, Brighenti, Matteo, additional, Crino, Lucio, additional, Dazzi, Claudio, additional, Tibaldi, Carmelo, additional, Turolla, Gianni Michele, additional, D'Alessandro, Vito, additional, Zilembo, Nicoletta, additional, Trolese, Anna Rita, additional, Grossi, Francesco, additional, Riccardi, Ferdinando, additional, and Ardizzoni, Andrea, additional

Published
2016
Full Text
View/download PDF

39. Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC).

Author

Toppo, Laura, primary, Tomasello, Gianluca, additional, Liguigli, Wanda, additional, Lazzarelli, Silvia, additional, Tanzi, Giulia, additional, Ghidini, Michele, additional, Perrucci, Bruno, additional, Brighenti, Matteo, additional, Ratti, Margherita, additional, Panni, Stefano, additional, Giganti, Maria Olga, additional, Donini, Maddalena, additional, Rovatti, Massimo, additional, Maglietta, Giuseppe, additional, Ranieri, Valerio, additional, Grassia, Roberto, additional, Iiritano, Elena, additional, Iezzi, ELISA, additional, Caminiti, Caterina, additional, and Passalacqua, Rodolfo, additional

Published
2016
Full Text
View/download PDF

40. 1632 LONG TERM RESULTS WITH BLADDER-SPARING APPROACH IN MIBC

Author

Brighenti Matteo, Luigi Benecchi, Rodolfo Passalacqua, Daniel Martens, Domenico Potenzoni, Andrea Prati, Donini Maddalena, Nicoletta Uliano, Antonio Savino, Michele Potenzoni, Annamaria Pieri, and Sergio Carmelo Destro Pastizzaro

Subjects
medicine.medical_specialty, business.industry, Urology, Medicine, Long term results, Bladder sparing, business
Published
2013

41. Optimizing chemotherapy in patients with metastatic transitional-cell carcinoma: High rate of complete response with two sequential dose-dense regimens of cisplatin, gemcitabine, paclitaxel, followed by MVAC.

Author

Passalacqua, Rodolfo, primary, Giganti, Maria Olga, additional, Brighenti, Matteo, additional, Perrucci, Bruno, additional, Donini, Maddalena, additional, Negri, Federica, additional, Tomasello, Gianluca, additional, Toppo, Laura, additional, Liguigli, Wanda, additional, Poli, Rossana, additional, Ratti, Margherita, additional, Benecchi, Luigi, additional, Prati, Andrea, additional, Arnaudi, Roberto, additional, Potenzoni, Michele, additional, Panni, Stefano, additional, and Lazzarelli, Silvia, additional

Published
2015
Full Text
View/download PDF

43. Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial

Author

Tomasello, Gianluca, primary, Liguigli, Wanda, additional, Poli, Rossana, additional, Lazzarelli, Silvia, additional, Brighenti, Matteo, additional, Negri, Federica, additional, Curti, Alessandra, additional, Martinotti, Mario, additional, Olivetti, Lucio, additional, Rovatti, Massimo, additional, Donati, Gianvito, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

44. Efficacy and safety of dose-dense modified TCF regimen (TCF-dd) in metastatic or locally advanced gastroesophageal cancer (GEC).

Author

Toppo, Laura, primary, Tomasello, Gianluca, additional, Liguigli, Wanda, additional, Ratti, Margherita, additional, Poli, Rossana, additional, Negri, Federica, additional, Curti, Alessandra, additional, Vismarra, Marco, additional, Maltese, Mariangela, additional, Delfrate, Roberto, additional, Donini, Maddalena, additional, Colombi, Chiara, additional, Brighenti, Matteo, additional, Panni, Stefano, additional, Perrucci, Bruno, additional, Lazzarelli, Silvia, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

45. Final analysis of efficacy and safety of dose-dense chemotherapy with modified TCF regimen (TCF-dd) in elderly patients (pts) with metastatic gastric cancer (MGC).

Author

Tomasello, Gianluca, primary, Liguigli, Wanda, additional, Poli, Rossana, additional, Ratti, Margherita, additional, Toppo, Laura, additional, Brighenti, Matteo, additional, Maltese, Mariangela, additional, Perrucci, Bruno, additional, Panni, Stefano, additional, Negri, Federica, additional, Lazzarelli, Silvia, additional, Colombi, Chiara, additional, Curti, Alessandra, additional, Donini, Maddalena, additional, Martinotti, Mario, additional, Rovatti, Massimo, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

46. Rate of durable complete remission (CR) using two sequential, dose-dense regimens of cisplatin, gemcitabine, paclitaxel (CGP) followed by m-VAC in patients with metastatic urothelial cancer (mUC).

Author

Brighenti, Matteo, primary, Panni, Stefano, additional, Perrucci, Bruno, additional, Maltese, Mariangela, additional, Liguigli, Wanda, additional, Tomasello, Gianluca, additional, Poli, Rossana, additional, Negri, Federica, additional, Ratti, Margherita, additional, Donini, Maddalena, additional, Toppo, Laura, additional, del Boca, Carlo, additional, Benecchi, Luigi, additional, Prati, Andrea, additional, Martens, Daniel, additional, Potenzoni, Michele, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

47. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by oxaliplatin, folinic acid, 5-fluorouracil, and irinotecan (COFFI) in locally advanced or metastatic gastric cancer (MGC).

Author

Tomasello, Gianluca, primary, Liguigli, Wanda, additional, Poli, Rossana, additional, Negri, Federica, additional, Brighenti, Matteo, additional, Toppo, Laura, additional, Curti, Alessandra, additional, Lazzarelli, Silvia, additional, Panni, Stefano, additional, Donini, Maddalena, additional, Maltese, Mariangela, additional, Ratti, Margherita, additional, and Passalacqua, Rodolfo, additional

Published
2012
Full Text
View/download PDF

48. Khorana risk score: Is the body mass index a predictable factor for thromboembolism in European countries? A retrospective analysis.

Author

Barni, Sandro, primary, Labianca, Roberto, additional, Verso, Melina, additional, Gasparini, Giampietro, additional, Bonizzoni, Erminio, additional, Mandala, Mario, additional, Brighenti, Matteo, additional, Petrelli, Fausto, additional, Bianchini, Carlo, additional, Perrone, Tania, additional, and Agnelli, Giancarlo, additional

Published
2012
Full Text
View/download PDF

50. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

Author

Barni, Sandro, primary, Labianca, Roberto, additional, Agnelli, Giancarlo, additional, Bonizzoni, Erminio, additional, Verso, Melina, additional, Mandalà, Mario, additional, Brighenti, Matteo, additional, Petrelli, Fausto, additional, Bianchini, Carlo, additional, Perrone, Tania, additional, and Gasparini, Giampietro, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results